Background {#Sec1}
==========

Metabolic syndrome, a well-known cluster of cardiovascular risk factors, is a major public health concern worldwide \[[@CR1], [@CR2]\]. Metabolic syndrome increases the risk for cardiovascular disease, diabetes, and even certain types of cancer \[[@CR3]\]. According to the National Cholesterol Education Program's Adult Treatment Panel III definition, metabolic syndrome is the presence of abnormal values for at least three of the following criteria: waist circumference, serum triglycerides, high-density lipoprotein (HDL) cholesterol, blood pressure, and fasting glucose \[[@CR3]\]. The prevalence of metabolic syndrome is increasing rapidly \[[@CR4]\]. According to data from the National Health and Nutrition Examination Survey (NHANES) 2011--2012, about 34.7% of US adults were estimated to have metabolic syndrome \[[@CR4]\]. Similar increasing trends have been observed in Europe and other countries \[[@CR2], [@CR5]\]. According to the National Cholesterol Education Program's Adult Treatment Panel III criteria, and per the World Health Organization Asia-Pacific guidelines, the prevalence of metabolic syndrome was approximately 28.2% in the general population of Korea in 2012 \[[@CR6]\]. The mortality rate due to cardiovascular disease has increased from 35.6 to 52.4 out of 100,000 persons over 2003--2014. Thus, more focus and effort is needed to reduce the prevalence of metabolic syndrome, while considering the rapidly increasing frequency of mortality due to related diseases \[[@CR7]\].

Thyroid hormones have an important role in metabolism \[[@CR8]\]. Abnormal levels of thyroid hormones alter metabolism, and some of these changes share common pathophysiologic processes with metabolic syndrome. Therefore, thyroid dysfunction can affect metabolic syndrome. Lambadiari et al. reported that thyroid hormones are significant determinants of glucose homeostasis \[[@CR9]\], and affect fasting glucose levels by antagonizing insulin action \[[@CR9]\]. For instance, hyperthyroidism leads to impaired insulin secretion, which suppresses hepatic glucose production and promotes glucose uptake in the muscle \[[@CR9]\]. Similarly, Dimitriadis et al. showed that the increased glucose levels in hyperthyroidism could be explained by an increase in endogenous glucose production via of gluconeogenesis \[[@CR10]\]. Studies have also demonstrated an association between thyroid hormones and glucose levels. Klein et al. reviewed several studies regarding the mechanism of action of thyroid hormones on the cardiovascular system \[[@CR11]\]. They concluded that thyroid hormones have direct and indirect impacts on the cardiovascular system. Patients with thyroid disease, especially hyperthyroidism, often demonstrated signs and symptoms of cardiovascular changes \[[@CR11]\]. Several other studies have shown that overt hypothyroidism induces an increase in blood pressure and plasma cholesterol levels \[[@CR12]\]. However, most of the studies that assessed the relationships between abnormal thyroid hormone levels and metabolic syndrome have been conducted in Caucasian populations \[[@CR2], [@CR13]\]. Therefore, the aim of this study was to assess the relationships between thyroid hormone levels and metabolic syndrome components in a nationally representative sample of South Korean adults.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

This study was conducted using data from the sixth Korea National Health and Nutrition Examination Surveys (KNHANES VI, 2013--2015), a nationwide cross-sectional survey conducted by the Korean Centers for Disease Control and Prevention (Seoul, Korea) to assess the health and nutritional status of the South Korean population. The institutional review board of the Korea Centers for Disease Control and Prevention (KCDC) approved the study (IRB: 2013-07CON-03-4C, 2013-12EXP-03-5C, 2015--01-02-6C). A nationally representative sample was obtained using a stratified multistage cluster sampling design. The survey consists of a health interview, nutrition survey, and health examination. Tests for thyroid disease and metabolic syndrome components (waist circumference, triglycerides, HDL cholesterol, blood pressure, and fasting glucose) were part of the health examination. The initial sample included 22,948 participants. The thyroid functions tests were carried out by subsampling 2400 subjects aged ≥10 years with respect to thyroid-stimulating hormone (TSH), free thyroxine (FT4), thyroid peroxidase antibody (TPOab), and urinary iodine in the sixth Korea National Health and Nutrition Examination Surveys (KNHANES VI, 2013--2015). Participants with missing thyroid function data were excluded (*n* = 20,591). Patients who received treatment that could interfere with the test results for thyroid hormone levels and various components of metabolic syndrome, such as radioactive iodine treatment, antithyroid drugs, thyroid hormones, other medication for thyroid disease, dyslipidemia medications, blood pressure regulators, insulin, or glucose regulators were also excluded (*n* = 429). The data for a total of 1423 participants without any missing variables were finally included in the analysis.

Dependent variables and variables of interest {#Sec4}
---------------------------------------------

The dependent variables were the components of metabolic syndrome. Waist circumference was measured at the narrowest spot between the lowest rib and the highest lateral border of the right iliac crest. Systolic blood pressure was measured after the participants relaxed for 5 min while sitting. Triplicate measurements of systolic blood pressure were obtained. The mean of the second and third measured value was used in the analysis. Triglycerides, HDL cholesterol, and fasting glucose levels were measured using the same Hitachi Automatic Analyzer 7600--210 (Hitachi, Tokyo, Japan).

The variable of interest in this study was thyroid hormone levels. Serum FT4, serum TSH, and TPOab levels were measured using an electro-chemiluminescence immunoassay (Cobas: Roche Diagnostics, Penzberg, Germany). Samples were sent to the central certified laboratory and analyzed. The laboratory reference ranges for FT4, TSH, and TPOab were 0.80--1.70 ng/dL, 0.50--5.0 uIU/mL, and \< 34 IU/mL \[[@CR14]--[@CR16]\]. FT4 levels were divided into five categories: (1) low; under normal (\< 0.80 ng/dL); (2) normal-low (\< 1.17 ng/dL); (3) normal-middle (\< 1.31 ng/dL); (4) normal-high (\< 1.70 ng/dL); and (5) high; upper normal (≥1.70 ng/dL). TSH levels were divided as follows: low; under normal (\< 0.50 uIU/mL); normal-low (\< 1.80 uIU/mL), normal-middle (\< 2.87 uIU/mL), normal-high (\< 5.00 uIU/mL) and high; upper normal (≥5.00 uIU/mL). TPOab levels were categorized as normal (\< 34 IU/mL), high with low FT4 (34 IU/mL ≤ TPOab; FT4 \< 1.24 ng/dL), high with high FT4 (34 IU/mL ≤ TPOab; 1.24 ng/dL ≤ FT4). In addition, we categorized TPOab levels into normal (\< 34 IU/mL), high with low TSH (34 IU/mL ≤ TPOab; TSH \< 2.25 uIU/mL), high with high TSH (34 IU/mL ≤ TPOab; 2.25 uIU/mL ≤ FT4). Considering that the TPOab titer is related to both hypothyroidism and hyperthyroidism, patients with high levels were divided into two groups using two median FT4 levels and two TSH levels.

Covariates {#Sec5}
----------

We adjusted for the covariates of sociodemographic factors, socioeconomic factors, health-behavior factors, and health-condition factors. Sociodemographic factors included age (19--44 years, 45--64 years, \> 64 years) and gender (male and female). Socioeconomic factors included educational level (elementary school or less, middle school, high school, and college or over), marital status (married and cohabit, married but no cohabit or bereaved or divorced, and unmarried), household income level (divided into quartiles), region (urban or rural), and occupation (white collar, pink collar, blue collar, and unemployed or else). Urban areas included capitals and metropolitan cities and rural areas comprised the remaining areas. Alcohol consumption (ever or never), smoking (ever or never), and walking activity (active or inactive) were the health-behavior factors. Health-condition factors involved stress level (high, middle, low).

Statistical analysis {#Sec6}
--------------------

Statistical analysis was performed using the SAS software, version 9.4 (SAS Institute, Cary, NC, USA). All analysis incorporated weights. The mean values and standard deviations of the components of metabolic syndrome were compared using the analysis of variance. Multiple linear regression was performed to analyze the relationship between thyroid hormone level and the components of metabolic syndrome. Subgroup analysis was performed according to age and gender. A *p*-value \< 0.05 was considered to indicate a statistically significant result.

Results {#Sec7}
=======

Demographic characteristics {#Sec8}
---------------------------

Table [1](#Tab1){ref-type="table"} presents the general characteristics of the study populations. There were 683 males (48.0%) and 740 females (52.0%) included in this study. Of the 1423 participants, 870 (61.1%) were aged between 19 and 44 years, 471 participants (33.1%) were aged between 45 and 64 years, and 82 participants (5.8%) were aged over 64 years. The mean waist circumference was 31.9 ± 4.0 in. and the mean triglycerides level was 133.0 ± 120.5 mg/dL. The mean HDL cholesterol level was 52.0 ± 12.8 mg/dL, mean blood pressure 114.2 ± 15.1 mmHg, and the mean fasting glucose level 95.0 ± 16.6 mg/dL. When analyzed according to FT4 levels, waist circumference, triglycerides, and fasting glucose results were statistically significantly different (*p* \< 0.05). Patients with high FT4 levels demonstrated considerably higher fasting glucose levels (High: 109.4 ± 45.2 mg/dL; Normal-middle: 93.8 ± 12.2 mg/dL).Table 1General characteristics of the study populationWaist circumference (inches)Triglycerides (mg/dL)HDL cholesterol (mg/dL)Blood pressure (mmHg)Fasting glucose (mg/dL)*N*%Mean ± SD*p*-valueMean ± SD*p*-valueMean ± SD*p*-valueMean ± SD*p*-valueMean ± SD*p*-valueTotal1423100.031.94.0133.0120.552.012.8114.215.195.016.6Free thyroxine hormone (ng/dL)0.03880.00200.18730.9267\<.0001 Low (\< 0.80)151.132.82.4162.774.451.813.4116.312.597.114.4 Normal (low tertile) (\< 1.17)42429.832.14.1141.3131.951.813.1114.616.095.916.8 Normal (mid tertile) (\< 1.31)48834.331.83.9133.9118.352.112.2113.915.693.812.2 Normal (high tertile) (\< 1.70)47233.231.94.2125.2114.952.213.2113.913.994.517.5 High (1.70≤)241.731.84.1102.153.048.27.2116.611.8109.445.2Thyroid stimulating hormone (uIU/mL)0.29650.98670.14890.69650.1958 Low (\< 0.50)302.130.82.9108.466.155.914.5116.314.294.910.9 Normal (low tertile) (\< 1.80)47633.532.14.1136.6144.851.313.1114.314.996.219.4 Normal (mid tertile) (\< 2.87)46832.932.14.0131.7111.952.112.5113.614.894.613.4 Normal (high tertile) (\< 5.00)33423.531.64.1132.0104.452.512.7114.716.094.818.4 High (5.00≤)1158.131.74.0132.996.051.612.3114.014.792.110.8Thyroid peroxidase antibody (IU/mL)0.52170.51890.40160.03690.9543 Normal (\< 34)132493.031.94.1132.2120.252.012.8114.015.195.117.0 High (under low FT4) (34≤)563.931.74.0155.3149.250.612.5114.413.192.610.1 High (under high FT4) (34≤)433.031.53.1127.979.651.513.7119.416.694.010.6Thyroid peroxidase antibody (IU/mL)0.99670.37550.54730.08270.5928 Normal (\< 34)132493.031.94.1132.2120.252.012.8114.015.195.117.0 High (under low TSH) (34≤)392.731.54.2124.869.950.512.5114.814.393.712.0 High (under high TSH) (34≤)604.231.63.3155.5148.551.313.4117.715.293.09.1Age0.44810.03470.0217\<.00010.0746 19--4487061.131.54.3125.1119.953.512.7109.912.292.916.7 45--6447133.132.63.4149.0126.950.013.0119.916.698.115.4 64\<825.832.93.4125.469.647.59.8126.116.898.319.3Gender\<.0001\<.0001\<.0001\<.0001\<.0001 Male68348.033.73.8166.2151.947.711.1118.414.298.020.1 Female74052.030.33.6102.468.355.913.0110.314.992.212.0Education level0.78440.57890.00020.00340.9794 Elementary school or less1198.432.83.1150.5114.046.311.0124.415.097.612.0 Middle school1087.632.64.2148.5105.850.611.6120.815.997.415.2 High school57440.331.94.0132.5126.453.013.2114.515.494.916.3 College or over62243.731.64.2127.4118.252.312.7110.813.394.117.8Marital status\<.00010.50170.05690.2066\<.0001 Married-cohabit81357.132.33.7136.4110.351.312.4116.016.396.717.9 Married-no co habit or bereaved or divorced1309.132.53.8147.0121.850.013.5118.015.598.818.4 Unmarried48033.731.14.5123.5135.253.812.9110.111.591.012.8Household income level0.03280.66710.16710.04840.4857 Quartile 1 (lowest)34624.332.54.3137.7125.951.313.0116.516.395.215.3 Quartile 233623.631.83.8124.2100.752.513.2113.514.294.818.1 Quartile 338627.131.93.8137.2115.651.012.4113.914.594.311.8 Quartile 4 (highest)35524.931.54.1132.2136.453.112.6112.715.195.620.5Region0.01630.01120.32900.67090.7321 Urban area104373.331.73.9127.4113.452.312.6113.615.194.616.4 Rural area38026.732.54.3148.5137.151.113.2115.914.996.017.2Occupation0.10360.7295\<.00010.59250.1260 White color44531.331.94.1132.0117.551.713.2111.413.594.919.3 Pink color20914.732.03.9126.295.852.912.5114.114.194.613.6 Blue color31522.133.03.6157.2147.951.413.3120.115.998.617.6 Unemployed or else45431.931.24.2120.3109.852.212.1112.915.492.713.8Alcohol consumption0.01080.33590.25790.88450.4812 Ever856.032.13.7123.295.351.513.9116.017.395.511.2 Never133894.031.94.1133.6121.952.012.7114.114.994.916.9Smoking0.00620.00250.56790.69790.3499 Ever60342.433.54.1167.2146.648.812.8117.515.097.216.3 Never82057.630.83.6107.988.954.212.3111.714.793.316.7Walking activity0.89150.38120.46420.08450.1128 Active58140.831.83.9127.3121.252.512.7112.714.393.513.8 Inactive84259.232.04.1137.0119.851.612.8115.215.596.018.3Stress level0.18670.04850.05670.13000.5092 High45131.731.94.4141.3145.751.912.6112.614.095.018.7 Middle80056.231.83.9128.1101.052.012.9114.015.194.714.9 Low17212.132.63.7134.0129.752.112.9119.116.996.218.5

Multiple analysis {#Sec9}
-----------------

Table [2](#Tab2){ref-type="table"} shows the estimates for the components of metabolic syndrome. "β" presents standardized regression coefficient and "S.E" presents standardized error of a correlation coefficient. After controlling for covariates, the results showed a positive association between FT4 and fasting glucose level in patients with high FT4 levels when compared to those with normal-middle FT4 levels (β = 15.992; *p =* \< 0.0001). We also identified a significant negative association between FT4 levels and triglycerides in patients with normal-high (β = − 21.145, *p* = 0.0054) and those with high FT4 levels (β = − 49.713, *p* = 0.0404). In addition, a positive association was observed between TPOab and triglycerides levels in patients with high TPOab levels in the presence of low median FT4 levels (β = 36.075, *p* = 0.0247). Also, positive association was identified between TPOab and triglycerides levels in patients with high TPOab levels in the presence of high median TSH levels (β = 32.181, *p* = 0.0368).Table 2The estimates for the components of metabolic syndromes^a^VariableWaist circumference (inches)Triglycerides (mg/dL)HDL cholesterol (mg/dL)Blood pressure (mmHg)Fasting glucose (mg/dL)β^a^S.E*p*-valueβ^a^S.E*p*-valueβ^a^S.E*p*-valueβ^a^S.E*p*-valueβ^a^S.E*p*-valueFree thyroxine hormone (ng/dL) Low (\< 0.80)1.3830.9380.140738.69030.1720.2000−0.2673.1090.93170.7583.5320.83012.7274.2170.5180 Normal (low tertile) (\< 1.17)0.3270.2400.17319.9577.7050.1964−0.2790.8010.7272−0.7120.9050.43131.6981.0770.1152 Normal (mid tertile) (\< 1.31)Ref.Ref.Ref.Ref.Ref. Normal (high tertile) (\< 1.70)− 0.4260.2360.0714−21.1457.5910.00541.4390.7880.0681−0.3590.8900.68690.2681.0610.8003 High (1.70≤)−0.7350.7530.3292−49.71324.2270.0404−1.7182.6030.50952.0682.8360.466115.9923.386\<.0001Thyroid stimulating hormone (uIU/mL) Low (\< 0.50)−1.2530.6730.0629−20.61421.7420.34324.3932.2270.04872.6562.5690.30140.1783.0400.9533 Normal (low tertile) (\< 1.80)−0.3180.2340.17420.4797.5590.9495−0.5580.7830.47590.6300.8800.47431.6801.0570.1122 Normal (mid tertile) (\< 2.87)Ref.Ref.Ref.Ref.Ref. Normal (high tertile) (\< 5.00)− 0.3780.2570.14143.5918.2970.66520.0350.8590.96711.2830.9660.18430.7131.1600.5392 High (5.00≤)−0.0930.3740.80449.04512.0950.4547−0.8901.2460.47480.6601.4060.6389−1.5111.6910.3717Thyroid peroxidase antibody (IU/mL)^b^ Normal (\< 34)Ref.Ref.Ref.Ref.Ref. High (under low FT4) (34≤)0.3960.4980.426836.07516.0460.0247−2.4751.6740.1396−0.8141.8660.6626−2.1522.2490.3387 High (under high FT4) (34≤)−0.6200.5560.2655−6.05417.9220.73560.1181.8620.94934.3192.0840.0384−1.6042.5120.5232Thyroid peroxidase antibody (IU/mL)^c^ Normal (\< 34)Ref.Ref.Ref.Ref.Ref. High (under low TSH) (34≤)−0.3070.5870.6014−5.24818.8950.7812−1.6171.9660.4110−0.4932.1980.8225−1.5112.6480.5682 High (under high TSH) (34≤)0.1110.4780.816232.18115.3960.0368−1.1301.6080.48252.7231.7910.1288−2.1692.1570.3149^a^Models is adjusted by age, gender, education level, marital status, household income level, region, occupation, alcohol consumption, smoking, walking activity and stress level^b^Considering that thyroid peroxidase antibody related to both hypothyroidism and hyperthyroidism, high groups were divided into two groups by two median of free thyroxine^c^Considering that thyroid peroxidase antibody related to both hypothyroidism and hyperthyroidism, high groups were divided into two groups by two median of thyroid stimulating hormone

Sensitivity analysis {#Sec10}
--------------------

Table [3](#Tab3){ref-type="table"} shows the subgroup analysis of the association between the components of metabolic syndrome and FT4 hormone levels according to age and gender. When stratified by age, a significant negative association between FT4 and triglycerides was observed among patients aged 19--44 years (low: β = 124.396, *p* = 0.0165; normal-high: β = − 25.519, *p* = 0.0050). This association was stronger in the 19--44-year-old age group than in the other older age groups.Table 3Subgroup analysis of components of metabolic syndromes with free thyroxine hormone levels stratified by age and genderVariablesFree thyroxine hormone levelsLowNormal (low tertile)Normal (mid tertile)Normal (high tertile)Highβ^a^S.E*p*-valueβ^a^S.E*p*-valueβ^a^β^a^S.E*p*-valueβ^a^S.E*p*-valueWaist circumferenceAge 19\~ 443.2481.7150.05860.4000.3450.2471Ref.−0.5370.3000.0738−1.0620.8920.2343 45\~ 640.7451.1130.50370.4700.3520.1818Ref.0.0780.4100.84950.3941.6680.8134 64\<−1.0853.6670.7684−0.0260.9270.9777Ref.−1.6381.2260.1868−3.9903.7050.2859Gender Male1.9982.1720.35800.8040.4050.0477Ref.−0.2700.3360.4206−0.6840.9570.4749 Female1.4810.9820.13220.0700.2840.8061Ref.−0.5560.3280.0909−2.0021.2770.1173TriglyceridesAge 19\~ 44124.39651.7980.016510.34110.4300.3217Ref.−25.5199.0660.0050−49.84326.9380.0646 45\~ 6422.88041.9550.585814.69913.2530.2680Ref.−11.08515.4410.4732−78.02662.8730.2153 64\<−29.03577.9250.7108−6.73719.6930.7335Ref.20.42426.0560.4363−21.24078.7440.7883Gender Male−8.75988.1500.920919.92616.4430.2260Ref.−29.60313.6190.0301−56.53638.8160.1457 Female59.24619.5380.00256.1755.6450.2744Ref.−8.7306.5270.1815−39.21025.3950.1230HDL cholesterolAge 19\~ 44−3.9875.3990.46050.1351.0960.9021Ref.2.5540.9520.0075−0.8672.9540.7692 45\~ 640.7994.2760.8518−1.3131.3600.3348Ref.−1.6871.5810.2868−5.8806.4080.3594 64\<6.57910.4350.5309−1.3602.6880.6149Ref.3.6633.5070.300710.07610.5810.3450Gender Male−4.9686.3730.4360−0.6611.2010.5824Ref.1.0280.9940.30170.3432.9810.9085 Female1.0033.7430.78880.0501.0890.9634Ref.1.9081.2560.1292−3.3084.8650.4968Blood pressureAge 19\~ 449.0815.0890.0747−0.0321.0290.9751Ref.0.6390.8930.47411.5602.6460.5556 45\~ 64−4.0075.6260.4767−2.5521.7790.1522Ref.−3.0812.0750.1382−1.7288.4390.8378 64\<−12.38720.1820.54175.3145.1010.3017Ref.−2.6106.7490.700322.08320.3950.2833Gender Male−12.6557.9950.11392.0731.4970.1666Ref.−0.4381.2390.72392.5753.5220.4649 Female4.8993.8700.2060−2.0821.1220.0638Ref.− 0.0011.2940.99963.3035.0300.5116Fasting glucoseAge 19\~ 44−3.8807.4210.60121.1901.4940.4261Ref.1.3331.2990.305017.1393.859\<.0001 45\~ 645.8955.2160.25911.8331.6480.2665Ref.−2.0491.9200.286514.2497.8170.0690 64\<13.83418.4400.4561−0.5924.6600.8994Ref.1.2486.1660.84033.02618.6330.8715Gender Male0.54511.5050.96233.9682.1460.0649Ref.−0.3351.7780.850621.2365.066\<.0001 Female3.2783.4800.34660.3461.0060.7307Ref.1.4311.1630.21875.1734.5240.2532^a^Model is adjusted by age, gender, education level, marital status, household income level, region, occupation, alcohol consumption, smoking, walking activity and stress level

Additional file [1](#MOESM1){ref-type="media"}: Table S1 presents the subgroup analysis of the association between the components of metabolic syndrome and TSH levels stratified by age and gender. Additional file [1](#MOESM1){ref-type="media"}: Table S2 shows the subgroup analysis of the association between the components of metabolic syndrome and TPOab levels with categorizing FT4 levels stratified by age and gender. In addition, Additional file [1](#MOESM1){ref-type="media"}: Table S3 shows the subgroup analysis of the association between the components of metabolic syndrome and TPOab levels with categorizing TSH levels stratified by age and gender. TSH was not significantly associated with other components of metabolic syndrome, except HDL cholesterol. Additional file [1](#MOESM1){ref-type="media"}: Table S2 shows that a positive association between TPOab and triglycerides levels is more frequently observed in male with high TPOab titers but with low FT4 levels (β = 136.104, *p* = 0.0062).

Discussion {#Sec11}
==========

The purpose of this study was to identify whether any associations exist between thyroid hormone levels and metabolic syndrome components. Thyroid dysfunction is well known to affect glucose and lipid metabolism; abnormal glucose level and abnormal lipid profile are important factors of metabolic syndrome \[[@CR17]\]. In our study, we found that glucose and lipid metabolism were associated with thyroid dysfunction. A significant positive association was observed between fasting glucose and FT4 in patients with high FT4 levels. In terms of lipid metabolism, a negative association between triglycerides and FT4 was observed among people with normal-high or high FT4 levels. In addition, there was a significant positive association between TPOab and triglycerides levels in patients with high thyroid peroxidase levels and with low median FT4 levels.

Thyroid hormones regulate carbohydrate metabolism \[[@CR18]\]. They influence the mRNA and protein expression of the glucose transporter 4, AMP-activated protein kinase, and acetyl CoA carboxylase in skeletal muscle \[[@CR19]\]. Hyperthyroidism usually occurs when high FT4 levels leads to its increased production and absorption from glycogen, lactic acid, glycerol, and amino acids \[[@CR20]\]. Hyperthyroidism can also increase insulin degradation. Which deteriorates blood glucose control \[[@CR19], [@CR20]\]. Based on these mechanisms, other studies also showed that glucose levels are high in patients with hyperthyroidism \[[@CR21]\]. Foss et al. demonstrated that patients with hyperthyroidism had higher blood glucose levels than the euthyroid participants, indicating increased endogenous glucose production \[[@CR22]\]. Moreover, Roubsanthisuk et al. reported that the higher glucose intolerance showed common in hyperthyroidism compare to the normal participants \[[@CR23]\]. This could be a major cause of the increased risk for diabetes \[[@CR23]\]. Health professionals should conduct follow-up tests of the glucose level of patients with high thyroid hormone levels. Additionally, thyroid hormone levels should be checked regularly in patients with high glucose levels.

A significant negative association between FT4 levels and triglycerides was observed in patients with high-normal or high FT4 levels. To explain this, we presumed that thyroid hormones play a key role in the regulation of enzyme activity during lipoprotein transport \[[@CR12]\]. The influence of thyroid function on lipid metabolism involves a pathophysiological process \[[@CR24]\]. The negative association observed between triglycerides and thyroid hormones can be explained by the increased removal rate of triglycerides from plasma due to an increase in the activity of hepatic triglyceride lipase \[[@CR25], [@CR26]\]. The effects of thyroid hormone on lipid metabolism are well known \[[@CR26]\]. Because the lipid profile tends to normalize improperly under high thyroid hormone levels, the lipid profile needs to be followed up after adjusting for thyroid hormone levels \[[@CR25]\].

There was a significant positive association between TPOab and triglycerides levels in patients with high thyroid peroxidase levels but with low median FT4 levels. In addition, a positive association was identified between TPOab and triglycerides levels in patients with high thyroid peroxidase levels in the presence of high median TSH levels. The presence of TPOab in the blood indicates a high risk for thyroid disease due to autoimmune disorders \[[@CR27], [@CR28]\]. In fact, abnormal TPOab levels were observed in 90% of patients with hypothyroidism and Graves' disease \[[@CR27], [@CR28]\]. Therefore, the positive association between TPOab and triglycerides levels in patients with high thyroid peroxidase levels but low median FT4 levels may be related to hypothyroidism.

Based on the results of the subgroup analysis, a significant negative association was observed between FT4 and triglyceride levels in patients aged 19--44 years; this association was stronger in the 19--44-year-old age group than in the other older age groups. This finding emphasizes the possibility of accumulation of risk through one's life course. Accumulation of various risks increases owing to illness, health-damaging behaviors, and adverse environmental conditions \[[@CR29]\]. Older people may have more risk factors owing to their risk accumulation, and are more likely to have unmeasured risk factors that we could not adjust for \[[@CR30]\]. To address this issue, future studies developed to understand the association between thyroid hormones and metabolic syndrome should incorporate a panel design.

This study had some limitations. First, the study was based on a cross-sectional survey. Causality could not be confirmed clearly and only the association could be confirmed. Second, one of the major thyroid hormones, triiodothyronine, was not used in the thyroid function tests. Despite the above limitations, this study also has a few strengths. First, consistent blood tests showed accurate blood TSH levels. Second, most of the previous studies were conducted in Caucasians; therefore, this issue is worth pursuing among Koreans. Finally, this study used the most recent (KNHANES 2013--2015) nationally, multistage, stratified collected data and could therefore be considered to be representative of the Korean population.

Conclusion {#Sec12}
==========

FT4 showed a partially positive association with fasting glucose, and a partially negative association with triglycerides in the general Korean population. Glucose level and lipid profile are metabolic syndrome components; metabolic syndrome is strongly correlated with diseases such as diabetes and cardiovascular disease that are associated with high mortality and morbidity rates. In patients with abnormal thyroid function, follow up tests for metabolic syndrome components during thyroid dysfunction could prevent overlooking metabolic syndrome and prevent related diseases.

Additional file
===============

 {#Sec13}

Additional file 1:**Table S1**. Subgroup analysis of components of metabolic syndromes with thyroid stimulating hormone levels stratified by age and gender. **Table S2**. Subgroup analysis of components of metabolic syndromes with thyroid peroxidase antibody levels stratified by age and gender. **Table S3**. Subgroup analysis of components of metabolic syndromes with thyroid peroxidase antibody levels stratified by age and gender. (DOCX 88 kb)
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